COMMUNIQUÉS West-GlobeNewswire

One World Products, Inc. Secures Exclusive Rights With Procepack for State-of-the-Art PreRoll-Er Equipment in Colombia

25/03/2024 - 13:00

LAS VEGAS, NV, March 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- One World Products, Inc. ("OWP") (OTCQB: OWPC), a trailblazer in hemp and cannabis production, proudly announces an exclusive agreement with [...]

Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection

25/03/2024 - 13:00

Currently Enrolling Phase 2 Study of BJT-778 in HDV; Interim Data Expected second half of 2024 SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a private clinical-stage biopharmaceutical [...]

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

25/03/2024 - 13:00

MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases [...]

Olink reports fourth quarter and full year 2023 financial results

25/03/2024 - 13:00

UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. Highlights Fourth [...]

Olink publishes 2023 annual report

25/03/2024 - 13:00

UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2023 is now available on the Company’s website at https://investors.olink. [...]

Novo Nordisk A/S - share repurchase programme

25/03/2024 - 12:58

Bagsværd, Denmark, 25 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

25/03/2024 - 11:30

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.008) AXS-12 [...]

Nkarta Announces Pricing of $240 Million Underwritten Offering

25/03/2024 - 11:30

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an [...]

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

25/03/2024 - 11:15

Reported positive topline data from the Phase 2b FASCINATE-2 trial; at week 52 denifanstat met both primary efficacy endpoints and demonstrated statistically significant reduction in fibrosis Presented late-breaking [...]

ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

25/03/2024 - 11:05

Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in January of 2024 as [...]

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

25/03/2024 - 11:00

VRG50635 is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform SOUTH SAN FRANCISCO, Calif. and BARCELONA, Spain, March 25, 2024 (GLOBE NEWSWIRE) -- [...]

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

25/03/2024 - 10:59

Bagsværd, Denmark, and Han n over, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront [...]

Novo Nordisk A/S - Articles of Association 2024

25/03/2024 - 08:51

Novo Nordisk's Articles of Association 2024 Attachment Articles of Association 21 Mar 2024

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

25/03/2024 - 07:05

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation First medical device company to become a corporate champion at the [...]

Nyxoah Fait Progresser sa Stratégie d'Accès aux Patients en Annonçant un Partenariat Stratégique avec l'American Association of Otolaryngology – Head & Neck Surgery Foundation

25/03/2024 - 07:05

Nyxoah Fait Progresser sa Stratégie d'Accès aux Patients en Annonçant un Partenariat Stratégique avec l'American Association of Otolaryngology – Head & Neck Surgery Foundation Première société de dispositifs [...]

Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy

25/03/2024 - 07:00

MOJAVE – US Phase 1/2a study of DSR 2.0 for treatment of heart failure Previously reported strong data maintained after three-months follow-up: Diuretic response remained nearly normalized, with a mean increase of 326% [...]

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

25/03/2024 - 07:00

Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) [...]

Valneva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son rapport annuel américain « Form 20-F »

25/03/2024 - 07:00

Saint-Herblain (France), 25 mars 2024 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui le dépôt, le 22 mars 2024, de son Document d’enregistrement universel [...]

Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024

25/03/2024 - 07:00

Oslo, March 25, 2024, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") at 14:00 CET on April 18, 2024. The General Meeting will be held electronically. For [...]